FC
EIGR

FORA Capital’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

FORA Capital’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-78
Closed -$23K – 1056
2020
Q2 		$23K Buy
78
+3
+4% +$884 0.01% 782
2020
Q1 		$15K Buy
+75
New +$23.9K ﹤0.01% 989

Other funds holding EIGR

6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

FORA Capital's EIGR Position: Q3 2020 in Review

FORA Capital sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q3 2020, closing a stake of 78 shares — an estimated $23K sold.

FORA Capital first reported a position in EIGR in Q1 2020 and held it in 2 quarters. The position peaked at $23K in Q2 2020. 102 funds tracked by Wall St. Rank hold EIGR as of Q3 2020.

  • FORA Capital reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • FORA Capital sold 78 Eiger BioPharmaceuticals, Inc. shares in Q3 2020, an estimated $23K.
  • FORA Capital first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2020 and held it in 2 quarters.
  • FORA Capital's Eiger BioPharmaceuticals, Inc. position peaked at $23K in Q2 2020.
  • 102 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q3 2020.

Based on FORA Capital's 13F filing for Q3 2020, filed 13 Nov 2020.